Skip to main content

Diagnostic Accuracy of Serum Insulin-Like Growth Factor Binding Protein-2 for Ovarian Cancer

Conference Correspondent

Insulin-like growth factor binding protein-2 (IGFBP2) plays an important role in the pathogenesis of ovarian cancer. It also serves as a potential biomarker in the evaluation of prognosis in patients with ovarian cancer. The role that IGFBP2 may play in the diagnosis of ovarian cancer is unknown. Researchers aimed to determine the diagnostic accuracy of serum IGFBP2 levels in differentiating between malignant and benign ovarian tumors.

In this study, the preoperative serum IGFBP2 level was assessed in 76 patients with adnexal mass who underwent exploratory laparotomy and subsequent histopathology examination. Of the 76 patients with adnexal mass, 46 were diagnosed with ovarian cancer. The remaining 30 patients were diagnosed with benign ovarian lesions.

The preoperative serum IGFBP2 level was significantly higher in patients diagnosed with ovarian cancer compared with those with benign lesions. The sensitivity of serum IGFBP2 for diagnosing ovarian cancer was 76.1% and specificity was 80%. The diagnostic odds ratio was 12.7. The diagnostic performance of IGFBP2 was enhanced in postmenopausal women, in whom sensitivity was 85% and specificity 85.7%, with a diagnostic odds ratio of 34. For patients with advanced-stage ovarian cancer, the sensitivity was 87.5% and specificity 80%, with a diagnostic odds ratio of 28.

Researchers conclude that serum IGFBP2 is a potential biomarker for the diagnosis of ovarian cancer. Increased sensitivity and specificity were observed in postmenopausal women and in patients with advanced-stage ovarian cancer. Preoperative IGFBP2 levels may have the potential to differentiate between malignant and benign ovarian tumors.

Abstract 54. ESGO 2020.

Related Items